Conference Call with Sequent Scientific Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Sequent Scientific announced Q1FY26 results Revenues: Rs 4,414 million compared to Rs 3,902 million during Q1FY25, change 13.1%. EBITDA: Rs 602 million compared to Rs 483 million during Q1FY25, change 24.7%. EBITDA Margin: 13.6% for Q1FY26. PAT: Rs 176 million compared to Rs 91 million during Q1FY25, change 93.7%. Rajaram Narayanan, Managing Director, said: “This quarter reinforces the momentum that we have built over the last 18 months, as we continue to deliver higher growth and profitability across all parts of the business. This has come on the back of initiatives in the areas relating to superior product mix, new launches and improved operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan and we expect all regulatory requirements to be completed in the next few months. We have commenced working on the Sequent 3.0 roadmap to leverage the synergies resulting from the merger and accelerate profitable revenue growth.” Result PDF
Pharmaceuticals company Sequent Scientific announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue stood at Rs 4,017 million, a growth of 11.2% YoY EBITDA rose to Rs 569 million, increasing by 38.7% YoY EBITDA Margin expanded by 280 bps, reaching 14.2% (vs. 11.4% in Q4FY24) FY25 Financial Highlights: Revenue came in at Rs 15,514 million, up 13.3% YoY EBITDA surged to Rs 1,993 million, marking a strong 86.6% YoY growth EBITDA Margin improved by 500 bps, rising to 12.8% (vs. 7.8% in FY24) Commenting on the Company’s performance, Rajaram Narayanan, Managing Director stated “This quarter reinforces the momentum that we have built in the business over the last 18 months. The significant improvement in profitability metrics and double-digit revenue growth has come on the back of several initiatives which have helped deliver a superior product mix, accelerate launches and improve operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan. The strong performance in FY 24-25 marks a turning point for us, as we prepare to accelerate the growth of the company and create the foundation for the Sequent 3.0 journey.” Result PDF
Conference Call with Sequent Scientific Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Sequent Scientific Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.